Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
SVA · Nasdaq · United States · Pharmaceutical Preparations
In shortSINOVAC BIOTECH LTD is loss-making, burns cash and holds more cash than debt, with revenue growing (+6.8% last year).
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -127.0% | 0/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -15.5% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -0.9% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | -7.5% | 0/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 4.59× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.11× | 100/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | Net cash | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | -49.92× | 0/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 7.10 | 100/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -145.4% | 0/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 1 of 5 | 0/100 |
Weight in the score: 20%
| Profitable years (last 5) | 3 of 5 | 60/100 |
|---|---|---|
| Years of revenue decline (last 5) | 3 of 5 | 0/100 |
| Revenue growth volatility | 1671.5% | 0/100 |
| Operating margin volatility | 102.4% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | -36.0% | 0/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 19,365 | 1,473 | 470 | 361 | 386 |
| Cost of revenue | 989 | 658 | 147 | 141 | 124 |
| Gross profit | 18,376 | 815 | 323 | 221 | 262 |
| Research & development | 153 | 479 | 350 | 271 | 216 |
| Selling, general & admin | 602 | 836 | 598 | 421 | 333 |
| Operating income | 17,618 | (509) | (714) | (506) | (490) |
| Interest expense | 2.8 | 1.3 | 4.9 | 5.6 | 9.8 |
| Pre-tax income | 17,568 | (48) | (84) | 43 | (262) |
| Income tax | 3,448 | 11 | 36 | 2.2 | (63) |
| Net income | 8,122 | 14 | (13) | 91 | (60) |
| Diluted EPS | $113.44 | $0.20 | −$0.19 | $1.27 | −$0.83 |
| Diluted shares (millions) | 72 | 72 | 72 | 72 | 72 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
7.10 Safe zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
3/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Dec 31, 2025 · Data updated Jun 5, 2026